Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,732
Completed, industry sponsors, Cardiovascular and metabolic, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting167
- Completed1,732
1,732 trials
Showing 1 to 25, recently updated first.
- A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and ObesityPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06037252 · 414 participants · Start Sep 21, 2023 · Primary completion Jan 8, 2026
Drug: Tirzepatide; Placebo · For: Type 2 Diabetes; Obesity
Sites: Phoenix, Arizona; Concord, California; Sacramento, California · 40 sites in all
- A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or OverweightPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06643728 · 252 participants · Start Oct 21, 2024 · Primary completion Jan 16, 2026
Drug: Bimagrumab; Tirzepatide and 2 more · For: Obesity; Overweight
Sites: Anniston, Alabama; Birmingham, Alabama; Walnut Creek, California · 12 sites in all
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT04567550 · 139 participants · Start Nov 20, 2020 · Primary completion Jun 18, 2026
Drug: Topical Steroid; Aflibercept · For: Diabetic Retinopathy (DR); Center-Involved Diabetic Macular Edema (CI-DME)
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 25 sites in all
Implicit BioscienceIndustry
NCT06556810 · 10 participants · Start Oct 17, 2024 · Primary completion Aug 30, 2026
Drug: Atibuclimab (IC14) · For: Acute Decompensated Heart Failure
Sites: Charlottesville, Virginia; Richmond, Virginia
- A Study Evaluating the Effect of Daily Oral Tifeglipron (RO7795081) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07081958 · 352 participants · Start Jul 29, 2025 · Primary completion Apr 28, 2026
Drug: Tifeglipron; Placebo · For: Obesity or Overweight
Sites: Anniston, Alabama; Lake Forest, California; Rancho Cucamonga, California · 36 sites in all
- A Clinical Trial of MT200605 for the Treatment of Acute Ischemic StrokePivotal-lookingCompleted
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT07205328 · 360 participants · Start Sep 30, 2025 · Primary completion Jun 12, 2026
Drug: MT200605; MT200605 and 2 more · For: Acute Ischemic Stroke
Sites: Beijing, China
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06299098 · 1,005 participants · Start Mar 13, 2024 · Primary completion Jun 16, 2026
Drug: Trevogrumab-Part A; Trevogrumab-Part B and Part C and 5 more · For: Obesity
Sites: Anniston, Alabama; Cullman, Alabama; Phoenix, Arizona · 60 sites in all
- A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05936151 · 146 participants · Start Jul 20, 2023 · Primary completion Oct 1, 2025
Drug: Retatrutide; Placebo · For: Overweight or Obesity; CKD; Type 2 Diabetes
Sites: Chandler, Arizona; Mesa, Arizona; Scottsdale, Arizona · 42 sites in all
- Next Generation RocklatanPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06441643 · 646 participants · Start Sep 4, 2024 · Primary completion Nov 14, 2025
Drug: AR-17043 Ophthalmic Solution; PG043 Ophthalmic Solution and 4 more · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Dothan, Alabama; Phoenix, Arizona; Garden Grove, California · 25 sites in all
Hope Biosciences LLCIndustry
NCT04063215 · 24 participants · Start Jan 1, 2020 · Primary completion Oct 25, 2024
Drug: HB-adMSCs · For: Traumatic Brain Injury
Sites: Houston, Texas
- UBT251 Injection Phase II (Type 2 Diabetes Mellitus) StudyPivotal-lookingCompleted
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07163624 · 211 participants · Start Mar 22, 2025 · Primary completion Nov 21, 2025
Drug: UBT251 Injection 2.0 mg and UBT251 Injection Placebo; UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo and 3 more · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Zhuhai, China
- UBT251 Injection Phase II Study (Overweight or Obesity)Pivotal-lookingCompleted
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07177469 · 205 participants · Start Mar 14, 2025 · Primary completion Oct 22, 2025
Drug: UBT251 Injection 2.0 mg and UBT251 Injection Placebo; UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo and 2 more · For: Obesity &Amp; Overweight
Sites: Changsha, China
- A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or OverweightPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT06973720 · 268 participants · Start Apr 7, 2025 · Primary completion Dec 16, 2025
Drug: MET097; Placebo · For: Obesity; Overweight or Obesity
Sites: Hollywood, Florida; Tampa, Florida; Atlanta, Georgia · 6 sites in all
Qlaris Bio, Inc.Industry
NCT07354477 · 9 participants · Start Feb 20, 2026 · Primary completion Oct 1, 2026
Drug: QLS-111 Ophthalmic Solution (0.015%); QLS-111 Ophthalmic Solution (0.075%) · For: Non-proliferative Diabetic Retinopathy (NPDR); Open-angle Glaucoma (OAG); Normal Tension Glaucoma (NTG)
Sites: Palo Alto, California
- A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT06924320 · 201 participants · Start Mar 6, 2025 · Primary completion Sep 29, 2026
Drug: MET233 and MET097; MET097 · For: Obesity and Obesity-related Medical Conditions
Sites: Cypress, California
Rhythm Pharmaceuticals, Inc.Industry
NCT06046443 · 28 participants · Start Jul 11, 2024 · Primary completion Feb 9, 2026
Drug: Bivamelagon; Placebo · For: Hypothalamic Obesity
Sites: Aurora, Colorado; Iowa City, Iowa; Boston, Massachusetts · 10 sites in all
- Study of the Safety and Efficacy of APX3330 in Diabetic RetinopathyPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT04692688 · 103 participants · Start Apr 8, 2021 · Primary completion Jan 25, 2023
Drug: APX3330; Placebo · For: Diabetic Retinopathy; Diabetic Macular Edema; NPDR - Non Proliferative Diabetic Retinopathy and 1 more
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 24 sites in all
- A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusPivotal-lookingCompleted
Ascletis Pharma (China) Co., LimitedIndustry
NCT07321678 · 100 participants · Start Jan 22, 2026 · Primary completion Aug 10, 2026
Drug: ASC30 tablets; Placebo · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Riverside, California; San Jose, California; Denver, Colorado · 8 sites in all
Opus Genetics, IncIndustry
NCT03960866 · 39 participants · Start May 28, 2019 · Primary completion Sep 11, 2019
Drug: Phentolamine Mesylate Ophthalmic Solution 1% · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Mission Hills, California; Morrow, Georgia; Ann Arbor, Michigan · 5 sites in all
EIP Pharma IncIndustry
NCT06987643 · 45 participants · Start Jun 20, 2025 · Primary completion Sep 23, 2026
Drug: Neflamapimod; Placebo · For: Moderate to Severe Acute Ischaemic Stroke; Ischaemic Stroke
Sites: Campbelltown, Australia; Liverpool, Australia; Birtinya, Australia · 10 sites in all
- A Study of CT-868 in Type 1 Diabetes MellitusPivotal-lookingCompleted
Carmot Therapeutics, Inc.Industry
NCT06062069 · 111 participants · Start Nov 27, 2023 · Primary completion Jul 7, 2025
Drug: CT-868; CT-868 Pen Injector, Placebo · For: Overweight; Obese; Type 1 Diabetes Mellitus
Sites: Concord, California; Escondido, California; Aurora, Colorado · 22 sites in all
- A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusPivotal-lookingCompleted
Carmot Therapeutics, Inc.Industry
NCT06628362 · 447 participants · Start Nov 21, 2024 · Primary completion May 29, 2026
Drug: Placebo; Enicepatide · For: Overweight or Obese; Type 2 Diabetes Mellitus (T2DM)
Sites: Birmingham, Alabama; Guntersville, Alabama; Yuma, Arizona · 70 sites in all
- A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05737940 · 260 participants · Start Apr 24, 2023 · Primary completion Jul 15, 2025
Drug: AZD3427; Placebo · For: Pulmonary Hypertension (World Health Organization Group 2); Heart Failure
Sites: Beverly Hills, California; La Jolla, California; New Haven, Connecticut · 60 sites in all
NodThera Ltd. (a Rezera company)Industry
NCT07220629 · 82 participants · Start Oct 2, 2025 · Primary completion Aug 21, 2026
Drug: NT-0796; Placebo · For: Obesity
Sites: Mesa, Arizona; Hialeah, Florida; Jacksonville, Florida · 9 sites in all
- Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)Pivotal-lookingCompleted
Biomea Fusion Inc.Industry
NCT05731544 · 443 participants · Start Aug 17, 2022 · Primary completion Nov 18, 2024
Drug: BMF-219; Placebo · For: Type 2 Diabetes Mellitus
Sites: Canoga Park, California; Fountain Valley, California; La Mesa, California · 39 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.